1. MARKETS
  2. SECTOR : CHEMICALS & PETROCHEMICALS
  3. INDUSTRY : SPECIALTY CHEMICALS
  4. TATVA CHINTAN PHARMA CHEM LTD.
Tatva Chintan Pharma Chem Ltd.
NSE: TATVA | BSE: 543321

Tatva Chintan Pharma Live Share Price Today, Share Analysis and Chart

Mid-range Performer
aboutTatva Chintan Pharma Chem Limited (TCPCL) is an integrated specialty chemical manufacturer based in India. Established in 1996 by first-generation technocrat entrepreneurs, the company operates across the entire value chain, from research and develop... Read More
Export DemandEBITDA per Kg
Ask AI about Tatva Chintan Pharma
1639.80-4.10(-0.25%)

57.05% Gain from 52W Low

20,607
NSE+BSE Volume

NSE 02 Nov, 2026 10:57 AM (IST)

Portfolio

Alert

My Notes

Loading...
- / 100
- / 100
50.1 / 100
Mid-range PerformerThese stocks have strong quality. Their reasonable financials and technicals make them potentially attractive to investorsView SimilarEmbed DVM
Analyst Price Target
-

19

S

6

W

10

O

1

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

15Positive8Negative

Pass in checklist65.2%

045
55
100

PE Valuation Check

Right Now
Undervalued
154.3%
1 Year Forward
Undervalued
212.9%
INSIGHTHigh 5Yr PE Avg of 155.0 may distort upside values.

Tatva Chintan Pharma Stock Price Analysis

Day Price Range

-0.2% 1 Day return
1639.8 (LTP)
1,579.11,650
LowHigh

Week Price Range

4.5% 1 Week return
1639.8 (LTP)
1,525.51,660
LowHigh

Month Price Range

-5.9% 1 Month return
1639.8 (LTP)
1,525.52,113.6
LowHigh

52 Week Price Range

15.3% 1 Year return
1639.8 (LTP)
1,044.12,113.6
LowHigh
View full Price History/Seasonality

Tatva Chintan Pharma Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Miss

Tatva Chintan Pharma's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

CURRENT EPS
18
AVG. ESTIMATE
33.1
LOW ESTIMATE
33.1
HIGH ESTIMATE
33.1
CURRENT EPS
AVG. ESTIMATE
Hit

EPS is expected to grow by 84.1% in FY27

Consensus Recommendation

4 ANALYST Recommendations
HOLD

The consensus recommendation from 4 analysts for Tatva Chintan Pharma is HOLD

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Tatva Chintan Pharma Technical Analysis

Tatva Chintan Pharma EMA & SMA

Bearish-2
3 bullish, 5 bearish
Bullish3
Bearish5
5 Day1638.8
10 Day1683.3
12 Day1697.6
20 Day1728.2
26 Day1734.4
50 Day1710.0
100 Day1613.9
200 Day1474.6

Tatva Chintan Pharma Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202646.0%
Week40.2%
Month34.8%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Tatva Chintan Pharma Resistance and Support

1628.33
Pivot
First Resistance1674.6
Second Resistance1705.2
Third Resistance1751.5
First Support1597.7
Second Support1551.4
Third Support1520.8
Day RSI42.8
Day MACD-36.8
Day MFI58.1
Day MACD Signal Line-4.5

Tatva Chintan Pharma Beta

1 Month0.9
1 Year1.2
3 Month1.1
3 Year0.8

Tatva Chintan Pharma Price Change Analysis

↓-5.9%
Over 1 Month
LowHigh
1525.52113.6
↓-8.3%
Over 3 Months
LowHigh
15202113.6
↑25.1%
Over 6 Months
LowHigh
11012113.6
↑15.3%
Over 1 Year
LowHigh
1044.12113.6
All Technicals →

Tatva Chintan Pharma Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Shekhar Rasiklal SomaniPromoter5,396,86123.1 %
Goldman Sachs Funds - Goldman Sachs India Equity PortfolioFii606,6622.6 %
Mukul Mahavir AgrawalPublic500,0002.1 %
Nippon Life India Trustee Ltd-A/C Nippon India Elss Tax Saver FundDii516,7002.2 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Tatva Chintan Pharma Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
GRAVITON RESEARCH CAPITAL LLPBulkSell15 Oct 20251212.74133,709NSE
MUSIGMA SECURITIESBulkSell15 Oct 20251262.51143,717NSE
MUSIGMA SECURITIESBulkPurchase15 Oct 20251262.14143,717NSE
GRAVITON RESEARCH CAPITAL LLPBulkPurchase15 Oct 20251210.89133,709NSE
GRAVITON RESEARCH CAPITAL LLPBulkSell25 Jul 20251153.92217,066NSE
MUSIGMA SECURITIESBulkSell25 Jul 20251171.36117,833NSE
GRAVITON RESEARCH CAPITAL LLPBulkPurchase25 Jul 20251152.08217,066NSE
MUSIGMA SECURITIESBulkPurchase25 Jul 20251170.74117,833NSE
GRAVITON RESEARCH CAPITAL LLPBulkSell18 Jul 20251035.79127,562NSE
GRAVITON RESEARCH CAPITAL LLPBulkPurchase18 Jul 20251035.16127,562NSE
All deals
All insider trades

Tatva Chintan Pharma Corporate Actions

Tatva Chintan Pharma Dividend history and yield

Tatva Chintan Pharma dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Tatva Chintan Pharma dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
111 Sep 2026
2FINAL11 Sep 2026Equity Share
212 Sep 2025
1FINAL12 Sep 2025Equity Share
306 Sep 2024
2FINAL-Equity Share
408 Sep 2023
2FINAL-Equity Share
508 Sep 2022
2FINAL09 Sep 2022Equity Share

Tatva Chintan Pharma Board Meetings

Tatva Chintan Pharma past and upcoming board meetings.

#Ex-Date
PurposeNotes
119 Oct 2026
Quarterly ResultsTo consider and approve the financial results for the period ended September 30, 2026
217 Jul 2026
Quarterly Results-
316 May 2026
Audited Results & Final Dividend-
421 Jan 2026
Quarterly Results-
531 Oct 2025
Quarterly Results-
All Corporate Actions

Tatva Chintan Pharma Research Reports

Tatva Chintan Pharma research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
126 Oct 2026Deven Choksey17601567.5Accumulate12.28%4.61%pdf
219 Oct 2026ICICI Securities Limited
Target
23851903.4Buy25.3%-13.85%pdf
319 Jul 2026Deven Choksey
Target
17651428.1Accumulate23.59%14.82%pdf
418 Jul 2026ICICI Securities Limited19551428.1Buy36.9%14.82%pdf
513 Jul 2026Deven Choksey
Target
14711391.4Accumulate5.72%17.85%pdf
All Reports of Tatva

Tatva Chintan Pharma Corporate Filings

Tatva Chintan Pharma BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
20 Oct 2026
Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication of Extract of Financial Results of the Company for the quarter and half year ended 30 September 2026.
PDF
19 Oct 2026
Tatva Chintan Pharma Chem Ltd - 543321 - Updated Investor Presentation
Updated Investor Presentation.
PDF
19 Oct 2026
Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the quarter and half year ended 30 September 2026.
PDF
19 Oct 2026
Q2FY27 Quarterly Result Announced for Tatva Chintan Pharma Chem Ltd.
Specialty Chemicals company Tatva Chintan Pharma Chem announced Q2FY27 results Consolidated Financial Highlights: Revenue from Operations: Stood at Rs 2,173.20 million in Q2FY27, up by 30.09% QoQ compared to Rs 1,670.55 million in Q1FY27 and up by 75.94% YoY compared to Rs 1,235.16 million in Q2FY26. Total Income: Stood at Rs 2,190.74 million in Q2FY27, reflecting an increase of 28.99% QoQ from Rs 1,698.35 million in Q1FY27 and an increase of 75.93% YoY from Rs 1,245.24 million in Q2FY26. Profit Before Tax (PBT): Stood at Rs 289.40 million in Q2FY27, growing by 37.08% QoQ compared to Rs 211.11 million in Q1FY27 and growing by 111.81% YoY compared to Rs 136.63 million in Q2FY26. Total Comprehensive Income: Stood at Rs 219.08 million in Q2FY27, showing a growth of 39.88% QoQ from Rs 156.62 million in Q1FY27 and a growth of 105.86% YoY from Rs 106.42 million in Q2FY26. Basic & Diluted Earnings Per Share (Face Value Rs 10/- each): Stood at Rs 9.17 per share in Q2FY27, up by 34.26% QoQ from Rs 6.83 per share in Q1FY27 and up by 116.27% YoY from Rs 4.24 per share in Q2FY26. Standalone Financial Highlights: Revenue from Operations: Stood at Rs 2,074.84 million in Q2FY27, up by 41.43% QoQ compared to Rs 1,467.02 million in Q1FY27 and up by 79.08% YoY compared to Rs 1,158.63 million in Q2FY26. Total Income: Stood at Rs 2,101.89 million in Q2FY27, rising by 39.44% QoQ from Rs 1,507.35 million in Q1FY27 and rising by 80.18% YoY from Rs 1,166.57 million in Q2FY26. Profit Before Tax (PBT): Stood at Rs 204.37 million in Q2FY27, higher by 45.01% QoQ compared to Rs 140.94 million in Q1FY27 and higher by 65.58% YoY compared to Rs 123.43 million in Q2FY26. Total Comprehensive Income: Stood at Rs 154.33 million in Q2FY27, registering a growth of 47.09% QoQ from Rs 104.92 million in Q1FY27 and a growth of 73.95% YoY from Rs 88.72 million in Q2FY26. Basic & Diluted Earnings Per Share (Face Value Rs 10/- each): Stood at Rs 6.57 per share in Q2FY27, rising by 46.98% QoQ compared to Rs 4.47 per share in Q1FY27 and rising by 71.99% YoY compared to Rs 3.82 per share in Q2FY26. Business Highlights: Group Structure & Consolidation: The consolidated financial results include the financial performance of the holding company, Tatva Chintan Pharma Chem Limited, along with its two wholly owned subsidiaries: Tatva Chintan USA Inc. Tatva Chintan Europe B.V. Exceptional Items: In Q1FY27, an exceptional item of Rs 13.18 million was recognized in both consolidated and standalone results. No exceptional items were incurred during Q2FY27, Q2FY26, or FY26. Result PDF
PDF
19 Oct 2026
Tatva Chintan Pharma Chem Ltd - 543321 - Intimation Regarding Cancellation Of Schedule Of Earnings Call
Earnings Call scheduled to be held on Monday, 19 October 2026 at 05:00 p.m. (IST) has been cancelled due to unforeseen circumstances.
PDF
VIEW ALL

Tatva Chintan Pharma DocumentsAsk MarketMind AI

Tatva Chintan Pharma Earnings Call

Tatva Chintan Pharma earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
21 Jul 2026Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
19 May 2026Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
24 Jan 2026Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
21 Jan 2026Tatva Chintan Pharma Chem Results Earnings Call for Q3FY26AudioVideo
04 Nov 2025Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAi summaryLink
view all

Tatva Chintan Pharma Annual Reports

Tatva Chintan Pharma financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2023Annual Report Mar-2023Link
2022Annual Report Mar-2022Link

Tatva Chintan Pharma Credit Ratings

Tatva Chintan Pharma credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
07 Sep 2026crisil ratingsTatva Chintan Pharma Chem LimitedTatva Chintan Pharma Chem Limited:Ratings upgraded to 'Crisil A- / Stable / Crisil A2+ 'Link
16 Aug 2026crisil ratingsTatva Chintan Pharma Chem LimitedRating Update : Tatva Chintan Pharma Chem LimitedLink
09 Jun 2025crisil ratingsTatva Chintan Pharma Chem LimitedTatva Chintan Pharma Chem Limited:Ratings downgraded to 'Crisil BBB+/Stable/Crisil A2'Link
05 Nov 2024crisil ratingsTatva Chintan Pharma Chem LimitedTatva Chintan Pharma Chem Limited:Rating outlook revised to 'Negative'; Ratings ReaffirmedLink
20 Sep 2023crisil ratingsTatva Chintan Pharma Chem LimitedTatva Chintan Pharma Chem Limited:Ratings reaffirmed at 'CRISIL A-/Stable/CRISIL A2+'; Rated amount enhanced for Bank DebtLink

Tatva Chintan Pharma Investor Presentations

Tatva Chintan Pharma investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
19 Oct 2026Tatva Chintan Pharma Chem Ltd - 543321 - Updated Investor PresentationLink
19 Oct 2026Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
17 Jul 2026Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
16 May 2026Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
21 Jan 2026Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

Tatva Chintan Pharma - Company Profile

Tatva Chintan Pharma Management Structure

Tatva Chintan Pharma management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Mr. Harish PatelHead - Operational Support-Mar 26
Mr. Rakeshkumar P. PooniaDeputy General Manager(Commercial)-Mar 26
Mr. Ajay RawatAssistant Vice President(Research & Development)-Mar 26
Mr. Ajesh PillaiChief Financial Officer-Mar 26
Ishwar NayiCompany Secretary,Compliance Officer-Mar 26

Tatva Chintan Pharma Board of Directors

Tatva Chintan Pharma Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Chintan Nitinkumar ShahChairman / Executive Director / M D / Promoter171.25Mar 25
Ajaykumar Mansukhlal PatelWTD & Executive Director171.25Mar 25
Shekhar Rasiklal SomaniWTD & Executive Director171.25Mar 25
Subhash PatelIndependent Non Exe. Director2.3Mar 25
Manher Chinmanlal DesaiIndependent Non Exe. Director2.1Mar 25
Avani Rajesh UmattIndependent Non Exe. Director1.9Mar 25
Ishwar NayiCompany Sec. & Compli. Officer-Mar 25
Website: www.tatvachintan.com

About the company - Business Profile

Tatva Chintan Pharma Chem Limited (TCPCL) is an integrated specialty chemical manufacturer based in India. Established in 1996 by first-generation technocrat entrepreneurs, the company operates across the entire value chain, from research and development to manufacturing and global distribution. It specializes in complex chemical processes, including conventional synthesis, electrolysis, and continuous flow chemistry. TCPCL holds a significant market position as a leading manufacturer of Phase Transfer Catalysts (PTC) and Structure Directing Agents (SDA), serving diverse industries such as pharmaceuticals, agrochemicals, and energy storage.

Key Points

  • Key Facts: Founded in 1996, headquartered in Vadodara, Gujarat. The company is listed on both the NSE and BSE (listed on July 29, 2021). It operates two wholly-owned subsidiaries: Tatva Chintan USA Inc. and Tatva Chintan Europe BV.
  • Operations and Resources: The company operates two manufacturing facilities in Ankleshwar and Dahej SEZ, Gujarat. As of March 31, 2025, the combined installed reactor capacity stood at 552 KL with 39 assembly lines. It also maintains a DSIR-approved R&D center in Vadodara.
  • Revenue Breakdown (FY 2024-25):
    • By Segment:
      • Pharma & Agrochemical Intermediates (PASC): 34%
      • Phase Transfer Catalyst (PTC): 33%
      • Structure Directing Agents (SDA): 31%
      • Electrolyte Salts (ESS): 2%
      • Others: 1%
    • By Geography: Exports accounted for 62% of the total revenue in FY25, with a customer base spanning over 25 countries, including the USA, UK, China, Germany, and Japan.
  • Financial Performance:
    • FY 2024-25: Revenue from operations was ₹382.71 crore, with an EBITDA of ₹34.21 crore (8.94% margin) and a PAT of ₹21.63 crore (5.71% margin).
    • 9M FY 2025-26: Revenue reached ₹371.71 crore, a 35% YoY increase. EBITDA (excluding other income) rose to ₹65 crore (17% margin), and PAT grew to ₹31.70 crore.
  • Key Products and Technology:
    • Structure Directing Agents (SDA): Critical for zeolite manufacturing used in emission control and petrochemicals.
    • Phase Transfer Catalysts (PTC): Used to facilitate reactions in heterogeneous multi-phase systems.
    • Electrolyte Salts: Cater to the supercapacitor batteries segment.
    • Technology: Utilization of continuous flow chemistry and electrolysis to enhance efficiency and promote green chemistry.
  • Clientele and Partnerships: TCPCL serves marquee global clients such as Merck, Bayer, SRF, Laurus Labs, Asian Paints, and Tosoh.
  • Employee Count: As of March 31, 2025, the company employed 679 personnel, a slight decrease from 689 in the previous year.
  • Strategic Initiatives and Outlook:
    • The company started a new distillation plant in Q4 FY25 to enhance operational capabilities.
    • Focus remains on expanding the product portfolio in the PASC and ESS segments to leverage the "China plus one" global manufacturing shift.
    • Maintains a low-leverage balance sheet with a debt-to-equity ratio of 0.02 as of March 2025.

References

  1. Annual Report May 2025
  2. Investor Presentation Jan 2026
  3. Investor Presentation Oct 2025
  4. Annual Report May 2024

Tatva Chintan Pharma FAQ

Tatva Chintan Pharma today is trading in the red, down by 0.25% at ₹1,639.8.
Tatva Chintan Pharma is currently trading down 0.25% on an intraday basis. In the past week the stock rose 4.49%. Stock has been down 8.3% in the past quarter and rose 15.29% in the past year. You can view this in the share price history/seasonality section.
Tatva Chintan Pharma is listed on NSE with the ticker TATVA and on BSE as 543321. It's currently trading on NSE at a share price of ₹1,639.8 and on BSE with a share price of ₹1,650.
The market cap of Tatva Chintan Pharma is ₹3,835.84 Cr. as of Nov 02, 2026.
Tatva Chintan Pharma announced a FINAL dividend of 20% which equals ₹2 in Sep 11, 2026.The last three ex-dates for Tatva Chintan Pharma were Sep 12, 2025, Sep 06, 2024 and Sep 08, 2023. To view the full dividend history of Tatva Chintan Pharma click here.
Tatva Chintan Pharma has never issued stock splits or bonus shares since the time of its listing on the BSE/NSE exchanges.
Tatva Chintan Pharma reported ₹219.07 Cr. in revenue, ₹21.45 Cr. in net profit, and ₹42.44 Cr. in EBITD as of Oct 19, 2026 for Q2 FY26-27.
According to the predictions of 4 analysts, the share price prediction for Tatva Chintan Pharma is ₹1,550 with a downside of 5%.
The PE ratio of Tatva Chintan Pharma is 60.97 as of Nov 02, 2026.
The PB ratio of Tatva Chintan Pharma is 4.81 as of Nov 02, 2026.
You can view the latest analyst reports on the Tatva Chintan Pharma reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×